Interní Med. 2007; 9(7): 314-317

Prevention of heart failure in primary outpatient care

prof. MUDr. Jindřich ©pinar CSc., FESC, prof. MUDr. Jiří Vítovec CSc
I. interní kardioangiologická klinika FN u sv. Anny v Brně

Chronic heart failure is called an epidemic of 21st century. Its increased prevalence is caused above all by aging of the population and improved care in acute situations, especially myocardial infarction. Under the term prevention of heart failure we understand an effective treatment of all situations leading to heart failure. It is mainly the treatment of hypertension with an adequate control of blood pressure and widespread use of blockers of renin-angiotensin system, control of metabolic parameters and modern therapy of ischemic heart disease both interventional and pharmacological. Healthy life style improves prognosis in patients with increased heart failure risk, but also in patients with an overt heart failure.

Keywords: prevention, hypertension, ischemia, ACE inhibitors

Published: December 18, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Vítovec J. Prevention of heart failure in primary outpatient care. Interní Med. 2007;9(7):314-317.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aschermann a kol: Kardiologie, Galén 2004; 1481 s.
    2. Baker DW. Prevention of heart failure. J Card Fail. 2002; 8: 333-346. Go to original source... Go to PubMed...
    3. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000; 160: 685-693. Go to original source... Go to PubMed...
    4. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869. Go to original source... Go to PubMed...
    5. Byteąník J. Doporučené postupy pro diagnostiku a léčbu komorových arytmií. Cor Vasa 2005; 47: S 9: 41-58.
    6. Cífková R, Býma S, Čeąka R, et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Cor et Vasa 2005; 47 (Suppl.) 3-14.
    7. Cleland JG, Swedberg K, Follath F et al. The Euro Heart Failure Survey Programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-463. Go to original source... Go to PubMed...
    8. Čihák R, Heinz P. Doporučení pro léčbu fibrilace síní. Cor et Vasa 2004; 46: K 46-78.
    9. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355: 253-259. Go to original source...
    10. Hradec J. Srdeční selhání - epidemie 21. století. Vnitř Lék 2004; 50 (Suppl. 1): S23-S31. Go to PubMed...
    11. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article: a report from the ACC/AHA task force on practice guidelines (writing committee to update the 2001 guidelines for the evolution and management of heart failure). Circulation. 2005; 112: 1825-1852. Go to original source...
    12. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001, 14: 70-73. Go to original source... Go to PubMed...
    13. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001; 20: 1016-1024. Go to original source... Go to PubMed...
    14. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
    15. Rosolova H, Cech J, Simon J, Spinar J, Jandova R, Widimsky J, Holubec J, Topolcan O. Short to long term mortality of patiens hospitalised in the Czech Republic - report from the EuroHeart Failure Survey. European Journal of Heart Failure 2005; 7 (5): 780-783. Go to original source... Go to PubMed...
    16. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001; 358: 1305-1315. Go to original source... Go to PubMed...
    17. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European society of cardiology. Eur Heart J. 2005; 26: 1115-1140. Go to original source... Go to PubMed...
    18. ©pinar J, Hradec J, Meluzín J, ©pác J, ©pinarová L, Vítovec J, Lupínek P, Málek I. Doporučení pro diagnostiku a léčbu srdečního selhání ČKS 2006. Cor et Vasa 2007; 49 (1): K 5-33.
    19. ©pinar J, Janský P, Kettner J, Málek I. Doporučení pro diagnostiku a léčbu akutního srdečního selhání. Cor et Vasa 2006; 48 (1): K3-31.
    20. ©pinar J, Vítovec J. Co by měl vědět internista o diastolickém srdečním selhání. Interní Med. 2005; 7 (12): 527-533.
    21. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000; 342: 145-153. Go to original source... Go to PubMed...
    22. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with CHF and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003; 362: 777-781. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.